Paraneoplastic neuromyopathy and neuropathy
ICD-10 G13.0 is a billable code used to indicate a diagnosis of paraneoplastic neuromyopathy and neuropathy.
Paraneoplastic neuromyopathy and neuropathy are neurological syndromes that occur as a consequence of cancer, where the immune response to a tumor inadvertently affects the nervous system. These conditions can manifest as muscle weakness, sensory disturbances, and autonomic dysfunction. The pathophysiology often involves the production of autoantibodies that target neuronal tissues, leading to inflammation and degeneration of peripheral nerves and muscle fibers. Clinically, patients may present with symptoms such as progressive weakness, ataxia, and sensory loss, which can mimic other neurological disorders. Diagnosis typically involves a combination of clinical evaluation, serological tests for specific onconeural antibodies, and electrophysiological studies. It is crucial to differentiate paraneoplastic syndromes from hereditary and degenerative diseases, such as Huntington's disease, various ataxias, and motor neuron diseases, as these conditions have distinct etiologies and management strategies. Early recognition and treatment of the underlying malignancy can lead to improvement in neurological symptoms, making timely diagnosis essential.
Detailed neurological examination findings, serological test results, and correlation with malignancy.
Patients presenting with unexplained muscle weakness or sensory changes in the context of known malignancy.
Ensure clear documentation of the relationship between neurological symptoms and cancer diagnosis.
Comprehensive cancer history, treatment details, and any neurological evaluations performed.
Cancer patients experiencing new neurological symptoms during or after treatment.
Documenting the timeline of neurological symptoms in relation to cancer diagnosis and treatment.
Used to evaluate muscle weakness in suspected paraneoplastic neuromyopathy.
Document the clinical rationale for the electromyography and findings.
Neurologists should ensure correlation with malignancy.
Common malignancies include lung cancer, breast cancer, and ovarian cancer, among others. The specific type of cancer can influence the type of neurological symptoms experienced.
